REGENEREX PHARMA, INC. financial data

Symbol
RGPX on OTC
Location
Las Vegas, NV
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 17 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.51 % +4486%
Debt-to-equity -118 % -0.26%
Return On Equity 69.4 % +117%
Return On Assets -389 % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 282M shares +1.4%
Common Stock, Shares, Outstanding 282M shares +1.19%
Entity Public Float 0 USD
Common Stock, Value, Issued 282K USD +1.19%
Weighted Average Number of Shares Outstanding, Basic 281M shares +1.14%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 136K USD
Selling and Marketing Expense 3K USD
General and Administrative Expense 1.94M USD +87.4%
Operating Income (Loss) -2.73M USD -165%
Nonoperating Income (Expense) -469K USD -43.5%
Income Tax Expense (Benefit) -50 USD
Net Income (Loss) Attributable to Parent -3.2M USD -136%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.7K USD +3866%
Assets, Current 48.4K USD +2539%
Property, Plant and Equipment, Net 5.23K USD
Operating Lease, Right-of-Use Asset 527K USD -15.7%
Assets 618K USD -2.4%
Accounts Payable, Current 219K USD +41.5%
Employee-related Liabilities, Current 808K USD +14.5%
Accrued Liabilities, Current 154K USD +22.2%
Liabilities, Current 4.92M USD +1.51%
Operating Lease, Liability, Noncurrent 393K USD -27.2%
Liabilities 5.32M USD -1.37%
Retained Earnings (Accumulated Deficit) -9.62M USD -49.9%
Stockholders' Equity Attributable to Parent -4.7M USD +1.23%
Liabilities and Equity 618K USD -2.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -478K USD -764%
Net Cash Provided by (Used in) Financing Activities -2.65K USD -105%
Net Cash Provided by (Used in) Investing Activities -3.63K USD
Common Stock, Shares Authorized 675M shares 0%
Common Stock, Shares, Issued 282M shares +1.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -481K USD -129092%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.7K USD +3866%
Deferred Tax Assets, Valuation Allowance 1.58M USD +51.4%
Depreciation 1.26K USD +10.1%
Operating Lease, Liability, Current 191K USD +15%
Deferred Tax Assets, Operating Loss Carryforwards 921K USD +98.5%
Additional Paid in Capital 4.64M USD +236%
Amortization of Intangible Assets 614 USD -78.6%
Interest Expense 77.9K USD -76.5%